VEA
Virtus ETF Advisers Portfolio holdings
AUM
$75.7M
1-Year Return
23.01%
This Quarter Return
+4.9%
1 Year Return
+23.01%
3 Year Return
+79.79%
5 Year Return
+153.94%
10 Year Return
–
AUM
$265M
AUM Growth
+$37.5M
(+17%)
Cap. Flow
+$31.7M
Cap. Flow
% of AUM
11.98%
Top 10 Holdings %
Top 10 Hldgs %
9.25%
Holding
421
New
24
Increased
206
Reduced
145
Closed
45
Top Buys
| 1 |
DT Midstream
DTM
|
$1.86M |
| 2 |
ScottsMiracle-Gro
SMG
|
$878K |
| 3 |
Valero Energy
VLO
|
$790K |
| 4 |
FMC
FMC
|
$775K |
| 5 |
Delek US
DK
|
$761K |
Top Sells
| 1 |
COR
Coresite Realty Corporation
COR
|
$1.67M |
| 2 |
XLRN
Acceleron Pharma Inc.
XLRN
|
$601K |
| 3 |
VTA
INVESCO DYNAMIC CREDIT OPPORTUNITIES FUND
VTA
|
$551K |
| 4 |
Travere Therapeutics
TVTX
|
$479K |
| 5 |
KDMN
Kadmon Holdings, Inc.
KDMN
|
$448K |
Sector Composition
| 1 | Real Estate | 22.39% |
| 2 | Healthcare | 18.38% |
| 3 | Energy | 15.88% |
| 4 | Materials | 14.07% |
| 5 | Utilities | 13.65% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
326
Arrowhead Research
ARWR
$3.84B
| $159K | 0.06% |
2,400
-3
| -0.1% | -$199 |
|
327
Day One Biopharmaceuticals
DAWN
$755M
| $159K | 0.06% |
+9,413
| New | +$159K |
|
328
Viking Therapeutics
VKTX
$2.94B
| $159K | 0.06% |
34,653
-318
| -0.9% | -$1.46K |
|
|
IMAB
329
I-MAB
IMAB
$350M
| $158K | 0.06% |
3,325
+400
| +14% | +$19K |
|
330
Legend Biotech
LEGN
$6.44B
| $158K | 0.06% |
3,384
-1,881
| -36% | -$87.8K |
|
331
Avidity Biosciences
RNA
$6.15B
| $158K | 0.06% |
6,664
-1,525
| -19% | -$36.2K |
|
|
GRCL
332
DELISTED
Gracell Biotechnologies Inc. American Depositary Shares
GRCL
| $158K | 0.06% |
26,197
+11,589
| +79% | +$69.9K |
|
|
PRVB
333
DELISTED
Provention Bio, Inc. Common Stock
PRVB
| $158K | 0.06% |
28,030
+4,363
| +18% | +$24.6K |
|
334
Geron
GERN
$874M
| $157K | 0.06% |
128,325
-18,293
| -12% | -$22.4K |
|
335
Passage Bio
PASG
$22.9M
| $157K | 0.06% |
1,235
+501
| +68% | +$63.7K |
|
336
Rocket Pharmaceuticals
RCKT
$345M
| $157K | 0.06% |
7,192
+2,686
| +60% | +$58.6K |
|
337
Akebia Therapeutics
AKBA
$806M
| $156K | 0.06% |
69,015
+10,772
| +18% | +$24.3K |
|
338
BioAtla
BCAB
$29.1M
| $155K | 0.06% |
7,912
+2,584
| +48% | +$50.6K |
|
339
Vor Biopharma
VOR
$243M
| $155K | 0.06% |
13,311
+3,778
| +40% | +$44K |
|
340
Arbutus Biopharma
ABUS
$751M
| $154K | 0.06% |
+39,675
| New | +$154K |
|
|
CMPS
341
Compass Pathways
CMPS
$481M
| $153K | 0.06% |
6,913
+1,474
| +27% | +$32.6K |
|
342
Cassava Sciences
SAVA
$104M
| $153K | 0.06% |
3,499
+701
| +25% | +$30.7K |
|
343
Editas Medicine
EDIT
$218M
| $152K | 0.06% |
5,740
+222
| +4% | +$5.88K |
|
344
Alaunos Therapeutics
TCRT
$4.27M
| $152K | 0.06% |
928
+448
| +93% | +$73.4K |
|
|
AUTL
345
Autolus Therapeutics
AUTL
$381M
| $151K | 0.06% |
+29,175
| New | +$151K |
|
346
Recursion Pharmaceuticals
RXRX
$1.96B
| $151K | 0.06% |
+8,821
| New | +$151K |
|
347
Caribou Biosciences
CRBU
$168M
| $150K | 0.06% |
+9,949
| New | +$150K |
|
|
SWTX
348
DELISTED
SpringWorks Therapeutics
SWTX
| $150K | 0.06% |
2,425
-215
| -8% | -$13.3K |
|
349
Verastem
VSTM
$632M
| $150K | 0.06% |
6,084
+2,338
| +62% | +$57.6K |
|
|
RETA
350
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
| $150K | 0.06% |
5,684
+4,198
| +283% | +$111K |
|